Teva fails to reclassify MS drug to thwart generics

05-01-2021

Muireann Bolger

Teva fails to reclassify MS drug to thwart generics

JHVEphoto / Shutterstock.com

Teva Pharmaceuticals has failed to redefine its multiple sclerosis drug Copaxone (glatiramer acetate) as a biological product instead of a drug, after the US District Court for the District of Columbia dismissed its efforts as “uncompetitive” on December 31.


Teva, multiple sclerosis drug, Copaxone, glatiramer acetate, biological product, drug, competition, generic

LSIPR